China Health Group (FRA:VNL1) ROCE % : -309.43% (As of Dec. 2023)

View and export this data going back to 2021. Start your Free Trial

What is China Health Group ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. China Health Group's annualized ROCE % for the quarter that ended in Dec. 2023 was -309.43%.

China Health Group ROCE % Historical Data

The historical data trend for China Health Group's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

China Health Group ROCE % Chart

China Health Group Annual Data

Trend

Dec12

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

ROCE %

Get a 7-Day Free Trial

73.70

79.10

32.35

-10.49

-49.80

China Health Group Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
ROCE %	Get a 7-Day Free Trial															-45.31	2.85	15.69	0.36	-309.43

China Health Group ROCE % Calculation

China Health Group's annualized ROCE % for the fiscal year that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2023 )		(A: Dec. 2022 )		(A: Dec. 2023 )
	=	-7.476	/	( ( (24.187 - 4.975)	+	(15.328 - 4.516) )	/ 2 )
	=	-7.476	/	( (19.212	+	10.812)	/ 2 )
	=	-7.476	/	15.012
	=	-49.80 %

China Health Group's ROCE % of for the quarter that ended in Dec. 2023 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2023 )		(Q: Sep. 2023 )		(Q: Dec. 2023 )
	=	-33.456	/	( ( (0 - 0)	+	(15.328 - 4.516) )	/ 1 )
	=	-33.456	/	( ( 0	+	10.812 )	/ 1 )
	=	-33.456	/	10.812
	=	-309.43 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

China Health Group (FRA:VNL1) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

China Health Group ROCE % Related Terms

Thank you for viewing the detailed overview of China Health Group's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

China Health Group (FRA:VNL1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » China Health Group Inc (FRA:VNL1) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

08225:Hong Kong

Address

Building 17, Jianwai SOHO, Chaoyang District, Beijing, CHN

Website

http://www.chgi.net

China Health Group Inc is an investment holding company engaged in providing medical care facilities in the People's republic of china. The company provides provision of post launch market research, medical and medical market services (PM services), Provision of contracted pharmaceutical development services (PD services), Provision of contracted clinical research services (CR Services), Drugs technologies, and Other medical services. The majority of the revenue for the company comes from the provision of PM services.

China Health Group (FRA:VNL1) Headlines

No Headlines